NASDAQ (usa) | 6715.56 | -12.11 | -0.18% | |
FTSE 100 (london) | 7487.96 | -5.12 | -0.07% | |
DAX (german) | 13465.51 | 235.94 | 1.78% | |
NIKKEI 225 (japan) | 22420.08 | 408.47 | 1.86% | |
Hang - Seng (hong kong) | 28594.06 | 348.52 | 1.23% |
NIFTY - 50 (india) | ||||
Straits Times (singapore) | 3391.61 | 17.53 | 0.52% | |
KOSPI (korea) | 2556.47 | 33.04 | 1.31% | |
All Ordinaries (australia) | 6005.30 | 28.90 | 0.48% | |
BOVESPA (brazil) | 74092.76 | -215.73 | -0.29% |
Jubilant Pharmova Limited (NSE: JUBLPHARMA)
JUBLPHARMA Technical Analysis
2
As on 9th Jan 2025 JUBLPHARMA SHARE Price closed @ 1002.95 and we RECOMMEND Buy for LONG-TERM with Stoploss of 861.71 & Strong Sell for SHORT-TERM with Stoploss of 1138.52 we also expect STOCK to react on Following IMPORTANT LEVELS. |
JUBLPHARMASHARE Price
Open | 1038.25 | Change | Price | % |
High | 1044.85 | 1 Day | -36.80 | -3.54 |
Low | 999.35 | 1 Week | -81.95 | -7.55 |
Close | 1002.95 | 1 Month | -162.10 | -13.91 |
Volume | 134562 | 1 Year | 436.75 | 77.14 |
52 Week High 722.45 | 52 Week Low 271.85 |
NSE INDIA Most Active Stocks
IDEA | 7.92 | -0.88% |
YESBANK | 18.49 | -1.49% |
HCC | 35.64 | -4.68% |
ZOMATO | 245.35 | -1.88% |
EASEMYTRIP | 15.14 | -1.69% |
MANAPPURAM | 179.00 | -0.54% |
SUZLON | 57.88 | -3.58% |
JYOTISTRUC | 25.50 | 1.39% |
TATASTEEL | 129.93 | -2.04% |
GTLINFRA | 1.94 | 0.00% |
NSE INDIA Top Gainers Stocks
KAMDHENU | 51.00 | 14.61% |
SRF | 2673.90 | 13.74% |
SRF | 2673.90 | 13.74% |
YUKEN | 1123.70 | 12.24% |
DNAMEDIA | 6.36 | 9.84% |
BALAMINES | 1909.05 | 9.65% |
NAVINFLUOR | 3824.55 | 9.49% |
GTPL | 146.52 | 8.46% |
ALKYLAMINE | 1870.20 | 7.56% |
GSLSU | 164.54 | 7.37% |
NSE INDIA Top Losers Stocks
JUBLPHARMA Daily Charts |
JUBLPHARMA Intraday Charts |
Whats New @ Bazaartrend |
JUBLPHARMA Free Analysis |
|
JUBLPHARMA Important Levels Intraday
RESISTANCE | 1090.63 |
RESISTANCE | 1062.51 |
RESISTANCE | 1045.13 |
RESISTANCE | 1027.75 |
SUPPORT | 978.15 |
SUPPORT | 960.77 |
SUPPORT | 943.39 |
SUPPORT | 915.27 |
JUBLPHARMA Target January 2025
4th UP Target | 1767.55 |
3rd UP Target | 1596.52 |
2nd UP Target | 1490.8 |
1st UP Target | 1385.08 |
1st DOWN Target | 1083.42 |
2nd DOWN Target | 977.7 |
3rd DOWN Target | 871.98 |
4th DOWN Target | 700.95 |
JUBLPHARMA Weekly Target
4th UP Target | 1236.38 |
3rd UP Target | 1190.03 |
2nd UP Target | 1161.38 |
1st UP Target | 1132.73 |
1st DOWN Target | 1050.98 |
2nd DOWN Target | 1022.33 |
3rd DOWN Target | 993.68 |
4th DOWN Target | 947.33 |
JUBLPHARMA Target2025
4th UP Target | 2733.32 |
3rd UP Target | 2211.17 |
2nd UP Target | 1888.42 |
1st UP Target | 1565.67 |
1st DOWN Target | 644.73 |
2nd DOWN Target | 321.98 |
3rd DOWN Target | -0.77 |
4th DOWN Target | -522.92 |
Jubilant Pharmova Limited ( NSE INDIA Symbol : JUBLPHARMA )
Sector : N/A And Other Stocks in Same Sector
Sector : N/A And Other Stocks in Same Sector
JUBLPHARMA Synopsis Technicals View
50 Day EMA |
N/A (Short Term) |
N/A | |
100 Day EMA | N/A (Mid Term) | N/A | |
200 Day EMA | N/A (Long Term) | N/A | |
MACD (12 26 9) | N/A | N/A | |
RSI (14) | N/A | N/A | |
MFI (14) | N/A | N/A | |
CCI (20) | N/A | N/A | |
WILLIAM %R (14) | N/A | N/A | |
ADX (14) | N/A | N/A | |
PSAR | N/A | N/A | |
10 Day Avg Volume | N/A |
JUBLPHARMA Other Details
Segment | EQ | |
Market Capital | 0.00 | |
Sector | ||
Industry | ||
Offical website | > echo $website ; ?> |
JUBLPHARMA Address
JUBLPHARMA Latest News
JUBLPHARMA Business Profile
N/A
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service